Search
Revolution Medicines Inc
RVMDAdd to Watchlist
204.630USD
-3.250-1.56%
Market hours 08/31, 15:26（ET）
40.96BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-28The current earnings forecast score of Revolution Medicines Inc is 8.64, ranking 92 out of 377 in the Biotechnology & Medical Research industry. The average price target is 76.50, with a high of 99.00 and a low of 70.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
247.162
Target Price
+18.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Revolution Medicines Inc
RVMD
22
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
Insmed Inc
INSM
24
IQVIA Holdings Inc
IQV
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Revolution Medicines Inc's expected revenue for the next quarter?
Revolution Medicines Inc's expected revenue is 2.42M.
What is Revolution Medicines Inc's price target?
Analysts forecast that Revolution Medicines Inc's price target is USD 76.50, with the highest forecast at USD 99.00 and the lowest forecast at USD 70.00.
How have Revolution Medicines IncRVMD's recent earnings per share performed?
The market expectation was USD -3.06, while Revolution Medicines IncRVMD's earnings per share (EPS) for the previous quarter was USD -2.29. EPS for the next quarter is expected at USD -2.45.
What is the analyst rating for Revolution Medicines Inc?
Based on the ratings of Revolution Medicines Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.